{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:44:49Z","timestamp":1785386689076,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Antibody therapy for chronic rhinosinusitis with nasal polyps (CRSwNP) has been established in Germany since 2019. With limited long-term data on biologic treatment for CRSwNP, we conducted a comprehensive evaluation of our 4-year data. This monocentric study aims to assess the real-world effects of this treatment on clinical course, quality of life, treatment adherence, biologic switching, dual therapy, and comorbidities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analysed biologic therapy data in patients with severe chronic rhinosinusitis with nasal polyps. 191 patients with CRSwNP treated with Dupilumab, Mepolizumab, or Omalizumab were observed for up to 4 years in a real-life setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We observed clear symptom improvements with few side effects. No loss of efficacy or tolerability was noted during the 4-year period. Patients reported high satisfaction compared to previous therapies, with overall improved quality of life. Revision surgery or oral steroid use during biologic therapy was rare. Some patients prolonged injection intervals or discontinued steroid nasal spray. Biologic switching occurred infrequently due to side effects or inadequate response and was generally well tolerated. Many patients reported additional positive effects such as asthma or allergy symptom improvement and reduced medication intake.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In summary, this study confirms the potency and tolerability of biologics for CRSwNP treatment, with sustained efficacy over 4 years. Biologic switching is a viable option for inadequate response or intolerable side effects. Therapy positively impacts Th2 comorbidities, corticosteroid requirements, surgery need, and overall compliance remains high.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>Project No.: 22\u20130802. Registry name: Biologika bei Patient*innen mit chronischer Sinusitis mit Nasenpolypen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-024-08790-y","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T20:21:54Z","timestamp":1720470114000},"page":"5773-5782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The use of biologics in patients suffering from chronic rhinosinusitis with nasal polyps \u2013 a 4-year real life observation"],"prefix":"10.1007","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7481-5321","authenticated-orcid":false,"given":"Hanna","family":"Frankenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9959-136X","authenticated-orcid":false,"given":"Robert","family":"Wiebringhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0510-3722","authenticated-orcid":false,"given":"Benedikt","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-2966","authenticated-orcid":false,"given":"Frank","family":"Haubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2243-7188","authenticated-orcid":false,"given":"Moritz","family":"Gr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5361-9830","authenticated-orcid":false,"given":"Clemens","family":"Stihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"8790_CR1","doi-asserted-by":"publisher","first-page":"e12200","DOI":"10.1002\/clt2.12200","volume":"12","author":"S Toppila-Salmi","year":"2022","unstructured":"Toppila-Salmi S, H\u00e4llfors J, Aakko J, Mannerstr\u00f6m B, Nieminen K, Telg G, Lehtim\u00e4ki L (2022) The burden of chronic rhinosinusitis with nasal polyps and its relation to asthma in Finland. Clin Transl Allergy 12:e12200. https:\/\/doi.org\/10.1002\/clt2.12200","journal-title":"Clin Transl Allergy"},{"key":"8790_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2016.05.041","volume":"138","author":"X Wang","year":"2016","unstructured":"Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, Wang H, Zhang L, Bachert C (2016) Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol 138:1344\u20131353. https:\/\/doi.org\/10.1016\/j.jaci.2016.05.041","journal-title":"J Allergy Clin Immunol"},{"key":"8790_CR3","first-page":"169","volume":"23","author":"C Grigoreas","year":"2002","unstructured":"Grigoreas C, Vourdas D, Petalas K, Simeonidis G, Demeroutis I, Tsioulos T (2002) Nasal polyps in patients with rhinitis and asthma. Allergy Asthma Proc 23:169\u2013174","journal-title":"Allergy Asthma Proc"},{"key":"8790_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/jaa.S290424","volume":"14","author":"C Bachert","year":"2021","unstructured":"Bachert C, Bhattacharyya N, Desrosiers M, Khan AH (2021) Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy 14:127\u2013134. https:\/\/doi.org\/10.2147\/jaa.S290424","journal-title":"J Asthma Allergy"},{"key":"8790_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/lio2.733","volume":"7","author":"DT Liu","year":"2022","unstructured":"Liu DT, Bartosik TJ, Campion NJ, Bayer K, Tu A, Victoria S, Besser G, Mueller CA, Gangl K, Eckl-Dorna J, Schneider S (2022) Chronic rhinosinusitis symptoms differentially impact the likelihood of major depressive disorders. Laryngoscope Investig Otolaryngol 7:29\u201335. https:\/\/doi.org\/10.1002\/lio2.733","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"8790_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert C, Han JK, Wagenmann M et al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 147:29\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013","journal-title":"J Allergy Clin Immunol"},{"key":"8790_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/all.13685","volume":"74","author":"K Jonstam","year":"2019","unstructured":"Jonstam K, Swanson BN, Mannent LP et al (2019) Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy 74:743\u2013752. https:\/\/doi.org\/10.1111\/all.13685","journal-title":"Allergy"},{"key":"8790_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1055\/a-1197-0136","volume":"99","author":"L Klimek","year":"2020","unstructured":"Klimek L, F\u00f6rster-Ruhrmann U, Becker S et al (2020) Positionspapier: anwendung Von biologika bei chronischer rhinosinusitis mit polyposis nasi (CRSwNP) Im Deutschen gesundheitssystem \u2013 empfehlungen des \u00e4rzteverbandes deutscher allergologen (AeDA) und Der AGs klinische immunologie, allergologie und umweltmedizin und rhinologie und rhinochirurgie Der Deutschen gesellschaft f\u00fcr HNO-heilkunde, kopf- und halschirurgie (DGHNOKHC). Laryngorhinootologie 99:511\u2013527. https:\/\/doi.org\/10.1055\/a-1197-0136","journal-title":"Laryngorhinootologie"},{"key":"8790_CR9","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","volume":"36","author":"S Chen","year":"2020","unstructured":"Chen S, Zhou A, Emmanuel B, Thomas K, Guiang H (2020) Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin 36:1897\u20131911. https:\/\/doi.org\/10.1080\/03007995.2020.1815682","journal-title":"Curr Med Res Opin"},{"key":"8790_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract 9:1133\u20131141. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8790_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00106-023-01273-2","volume":"71","author":"O Pfaar","year":"2023","unstructured":"Pfaar O, Beule AG, Laudien M, Stuck BA (2023) Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with monoclonal antibodies (biologics): S2k guideline of the German society of Oto-Rhino-Laryngology, Head and Neck surgery (DGHNO-KHC), and the German College of General Practitioners and Family Physicians (DEGAM). HNO 71:256\u2013263. https:\/\/doi.org\/10.1007\/s00106-023-01273-2","journal-title":"HNO"},{"key":"8790_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P, Omachi TA, Corren J et al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146:595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"key":"8790_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ, Viskens AS, Backer V et al (2023) EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology 61:194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489","journal-title":"Rhinology"},{"key":"8790_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, Van Cauwenberge P, Bachert C (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131:110\u2013116e1. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.047","journal-title":"J Allergy Clin Immunol"},{"key":"8790_CR15","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.3390\/jcm11102684","volume":"11","author":"E De Corso","year":"2022","unstructured":"De Corso E, Settimi S, Montuori C et al (2022) Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a real-life observational study in the first year of treatment. J Clin Med 11:2684. https:\/\/doi.org\/10.3390\/jcm11102684","journal-title":"J Clin Med"},{"key":"8790_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4193\/Rhin22.408","volume":"61","author":"FF Brkic","year":"2023","unstructured":"Brkic FF, Liu DT, Klimbacher R et al (2023) Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD. Rhinology 61:320\u2013327. https:\/\/doi.org\/10.4193\/Rhin22.408","journal-title":"Rhinology"},{"key":"8790_CR17","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/1744666x.2023.2218617","volume":"19","author":"J Otten","year":"2023","unstructured":"Otten J, Van der Lans R, De Corso E et al (2023) Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making. Expert Rev Clin Immunol 19:1041\u20131049. https:\/\/doi.org\/10.1080\/1744666x.2023.2218617","journal-title":"Expert Rev Clin Immunol"},{"key":"8790_CR18","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.3390\/jcm12134374","volume":"12","author":"K Gerstacker","year":"2023","unstructured":"Gerstacker K, Ketterer MC, Jakob TF, Hildenbrand T (2023) Real life observational study of treatment success of monoclonal antibodies for refractory chronic rhinosinusitis with nasal polyps. J Clin Med 12:4374. https:\/\/doi.org\/10.3390\/jcm12134374","journal-title":"J Clin Med"},{"key":"8790_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/s0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394:1638\u20131650. https:\/\/doi.org\/10.1016\/s0140-6736(19)31881-1","journal-title":"Lancet"},{"key":"8790_CR20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/19458924231153485","volume":"37","author":"HA Qureshi","year":"2023","unstructured":"Qureshi HA, Lane AP (2023) Olfaction now and in the future in CRSwNP. Am J Rhinol Allergy 37:168\u2013174. https:\/\/doi.org\/10.1177\/19458924231153485","journal-title":"Am J Rhinol Allergy"},{"key":"8790_CR21","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","volume":"78","author":"RJL Van der Lans","year":"2023","unstructured":"Van der Lans RJL, Otten JJ, Adriaensen G, Hoven DR, Benoist LB, Fokkens WJ, Reitsma S (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy 78:2684\u20132697. https:\/\/doi.org\/10.1111\/all.15796","journal-title":"Allergy"},{"key":"8790_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40248-016-0054-3","volume":"11","author":"D Passali","year":"2016","unstructured":"Passali D, Spinosi MC, Crisanti A, Bellussi LM (2016) Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med 11:18. https:\/\/doi.org\/10.1186\/s40248-016-0054-3","journal-title":"Multidiscip Respir Med"},{"key":"8790_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23325","author":"CM Low","year":"2024","unstructured":"Low CM, Wang AR, Yong M, Nayak J, Patel Z, Hwang PH (2024) Impact of dupilumab prescribing on utilization of medical and surgical therapies for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.23325","journal-title":"Int Forum Allergy Rhinol"},{"key":"8790_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11882-023-01106-w","volume":"23","author":"J Maza-Solano","year":"2023","unstructured":"Maza-Solano J, Callejon-Leblic A, Martin-Jimenez D, Moreno-Luna R, Gonzalez-Garcia J, Cuvillo A, Sanchez-Gomez S (2023) Omalizumab treatment in uncontrolled asthma and CRSwNP patients, with previous endoscopic sinus surgery, to improve quality of life and endoscopic outcomes: a two-year real-life study. Curr Allergy Asthma Rep 23:555\u2013566. https:\/\/doi.org\/10.1007\/s11882-023-01106-w","journal-title":"Curr Allergy Asthma Rep"},{"key":"8790_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/19458924221147501","volume":"37","author":"N Chapurin","year":"2023","unstructured":"Chapurin N, Khan S, Gutierrez J, Soler ZM (2023) Economics of medical and surgical management of chronic rhinosinusitis with nasal polyps: a contemporary review. Am J Rhinol Allergy 37:227\u2013231. https:\/\/doi.org\/10.1177\/19458924221147501","journal-title":"Am J Rhinol Allergy"},{"key":"8790_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/lary.24401","volume":"124","author":"JG Krings","year":"2014","unstructured":"Krings JG, Kallogjeri D, Wineland A, Nepple KG, Piccirillo JF, Getz AE (2014) Complications of primary and revision functional endoscopic sinus surgery for chronic rhinosinusitis. Laryngoscope 124:838\u2013845. https:\/\/doi.org\/10.1002\/lary.24401","journal-title":"Laryngoscope"},{"key":"8790_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.iac.2015.12.002","volume":"36","author":"EO Meltzer","year":"2016","unstructured":"Meltzer EO (2016) Allergic rhinitis: burden of illness, quality of life, comorbidities, and control. Immunol Allergy Clin North Am 36:235\u2013248. https:\/\/doi.org\/10.1016\/j.iac.2015.12.002","journal-title":"Immunol Allergy Clin North Am"},{"key":"8790_CR28","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","volume":"10","author":"J Mullol","year":"2022","unstructured":"Mullol J, Azar A, Buchheit KM, Hopkins C, Bernstein JA (2022) Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era. J Allergy Clin Immunol Pract 10:1434\u20131453e9. https:\/\/doi.org\/10.1016\/j.jaip.2022.03.002","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8790_CR29","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert C, Han JK, Desrosiers MY et al (2022) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol 149:1309\u20131317e12. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.030","journal-title":"J Allergy Clin Immunol"},{"key":"8790_CR30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/19458924221112211","volume":"36","author":"L De Prado Gomez","year":"2022","unstructured":"De Prado Gomez L, Khan AH, Peters AT, Bachert C, Wagenmann M, Heffler E, Hopkins C, Hellings PW, Zhang M, Xing J, Rowe P, Jacob-Nara JA (2022) Efficacy and safety of dupilumab versus omalizumab in chronic rhinosinusitis with nasal polyps and asthma: EVEREST trial design. Am J Rhinol Allergy 36:788\u2013795. https:\/\/doi.org\/10.1177\/19458924221112211","journal-title":"Am J Rhinol Allergy"},{"key":"8790_CR31","doi-asserted-by":"publisher","first-page":"CD013513","DOI":"10.1002\/14651858.CD013513.pub3","volume":"3","author":"LY Chong","year":"2021","unstructured":"Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, Hopkins C, Burton MJ (2021) Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev 3:CD013513. https:\/\/doi.org\/10.1002\/14651858.CD013513.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"8790_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000519228","volume":"183","author":"Q Wu","year":"2022","unstructured":"Wu Q, Zhang Y, Kong W, Wang X, Yuan L, Zheng R, Qiu H, Huang X, Yang Q (2022) Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis. Int Arch Allergy Immunol 183:279\u2013288. https:\/\/doi.org\/10.1159\/000519228","journal-title":"Int Arch Allergy Immunol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-08790-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T08:48:38Z","timestamp":1730105318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-08790-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["8790"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-08790-y","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Projekt Nr.: 22\u20130802.Consultation and approval of the study: \u201cBiologics in patients with chronic sinusitis with nasal polyps\u201d according to the Declaration of Helsinki \/ \u00a7\u00a015 Professional Code of Conduct for Physicians in Bavaria \/ Consultation according to the applicable faculty law of the LMU on 06.02.2023. The Ethics Committee (EC) can approve the ethical and legal acceptability of your study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants were individually informed verbally and in writing about their participation in the study and gave their informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants were individually informed verbally and in writing about the purpose of the study and gave their informed consent to the publication of the data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"MG declares consulting fees from Sanofi, GSK and Novartis. FH declares consulting fees from Brainlab und Spiggle&Theis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}